DermTech, Inc.

Equities

DMTK

US24984K1051

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 09:05:25 23/05/2024 pm IST			5-day change	1st Jan Change
0.375 ^USD	-10.71%		-35.21%	-78.86%

14/05	Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M	MT
22/04	North American Morning Briefing : Stock Futures -2-	DJ

DermTech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 05, 2023 at 02:04 am IST

DermTech, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 0.052 million compared to USD 0.2 million a year ago. Revenue was USD 3.48 million compared to USD 3.72 million a year ago.

Net loss was USD 31.27 million compared to USD 30.11 million a year ago. Basic loss per share from continuing operations was USD 1.02 compared to USD 1.01 a year ago. Diluted loss per share from continuing operations was USD 1.02 compared to USD 1.01 a year ago.

Latest news about DermTech, Inc.

Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M	15/05	MT
North American Morning Briefing : Stock Futures -2-	22/04	DJ
Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63	19/04	MT
BTIG Downgrades DermTech to Neutral From Buy	19/04	MT
DermTech Explores Strategic Alternatives to Boost Shareholder Value, Lays Off 100 Employees in Restructuring Plan	19/04	MT
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18/04	CI
BTIG Adjusts DermTech's Price Target to $2 From $4, Maintains Buy Rating	07/03	MT
Stephens Trims Price Target on DermTech to $1.50 From $2.50, Keeps Equalweight Rating	05/03	MT
Transcript : DermTech, Inc., Q4 2023 Earnings Call, Feb 29, 2024	01/03
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI
Earnings Flash (DMTK) DERMTECH Reports Q4 Revenue $3.9M, vs. Street Est of $4.03M	01/03	MT
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer	01/02	CI
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types	18/01	CI
DermTech, Inc. Simplifies the DermTech Melanoma Test by Discontinuing the Optional TERT Add-On Assay	16/01	CI
Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test	08/01	CI
Transcript : DermTech, Inc., Q3 2023 Earnings Call, Nov 02, 2023	03/11
DermTech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Earnings Flash (DMTK) DERMTECH Posts Q3 Revenue $3.9M, vs. Street Est of $3.9M	03/11	MT
DermTech Signs Contract With Highmark For Enhanced Access to DermTech Melanoma Test	19/23/19	MT
DermTech Inc Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test	19/23/19	CI
Dermtech Appoints Mark Aguillard as Chief Commercial Officer	11/23/11	CI
BTIG Adjusts Price Target on DermTech to $5 From $6, Maintains Buy Rating	07/23/07	MT
Transcript : DermTech, Inc., Q2 2023 Earnings Call, Aug 03, 2023	04/23/04
DermTech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04	CI

Chart DermTech, Inc.

Duration

Period

More charts

Company Profile

DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.

Sector

Medical Equipment, Supplies & Distribution

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for DermTech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.42 USD

Average target price

2.043 USD

Spread / Average Target

+386.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
DERMTECH, INC.	-78.86%	1.45Cr
BIOMÉRIEUX	-6.11%	1.21TCr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.26%	820.93Cr
DIASORIN S.P.A.	+5.21%	573.9Cr
LANTHEUS HOLDINGS, INC.	+29.65%	563.82Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-9.05%	415.71Cr
10X GENOMICS, INC.	-58.10%	288.14Cr
ANDON HEALTH CO., LTD.	+11.87%	268.69Cr
VITROLIFE AB	-5.08%	232.56Cr
MYRIAD GENETICS, INC.	+24.06%	217.13Cr

Diagnostic & Testing Substances